Open-label, Single-blinded, Observational, Prospective, 24-months, Longitudinal, Controlled Study to Assess the Efficacy of Gilenya® on Development of Thalamus Pathology and Cognitive Impairment in Patients With Relapsing Forms of Multiple Sclerosis.
Phase of Trial: Phase IV
Latest Information Update: 18 Apr 2019
Price : $35 *
At a glance
- Drugs Fingolimod (Primary)
- Indications Multiple sclerosis
- Focus Pharmacodynamics
- Acronyms GLT
- 15 Apr 2019 Status changed from active, no longer recruiting to completed.
- 01 May 2017 Planned End Date changed from 1 Jan 2017 to 1 Oct 2018.
- 01 May 2017 Planned primary completion date changed from 1 Oct 2016 to 1 Sep 2018.